Co-Founder and CTO
Dr. Michael V. Chobotov Ph.D. is CoFounder Chief Technology Officer of TriVascular Technologies Inc. He currently serves as our Chief Technology Officer and served as a member of our Board until April 2014. Prior to cofounding TriVascular in 1998 Dr. Chobotov cofounded TransMotive Technologies an engineering and product development consulting company. Previously Dr. Chobotov served as Senior Vice President of RD and board member of U.S. Electricar and Senior Systems Engineer at Hughes Space and Communications. He also led the design of the Lunar Prospector which was subsequently implemented as the first NASA Discovery mission
Age: 53 Founder Since 2014
Chobotov received his Ph.D. in Mechanical Engineering, his M.S. in Mechanical Engineering and his B.S. in Engineering and Applied Science, all from the California Institute of Technology.
Michael Chobotov Latest Insider Activity
The company has return on total asset (ROA)
of (0.57) %
which means that it has lost $0.57 on every $100 spent on asset. This is way below average.
The company currently holds 55 M in liabilities with Debt to Equity (D/E) ratio of 1.74 which is about average as compared to similar companies. TriVascular Technologies Inc has Current Ratio of 6.98 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
TriVascular Technologies, Inc., a medical device company, develops and commercializes technologies to advance minimally invasive treatment of abdominal aortic aneurysms . TriVascular Technologies Inc (TRIV) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 307 people. TriVascular Technologies is listed under Medical Equipment category by Fama And French industry classification.